water resources, groundwater resources, biological resources, selenium bioaccumulation, geology and seismicity, energy resources, air resources, agricultural production and economics, land use and soil resources, recreational resources, cultural resources, aesthetics, regional economics, and social issues and environmental justice. Reclamation determined that the action alternatives were unlikely to affect traffic and transportation, noise, utilities and public services, and Indian Trust Assets.

Copies of the Final EIS are available for review and inspection at the following public libraries:

- Bureau of Reclamation, Denver Office Library, Building 67, Room 167, Denver Federal Center, 6th and Kipling, Denver, CO 80225; telephone 303–445–2072;
- Bureau of Reclamation, Mid-Pacific Regional Library, 2800 Cottage Way, Sacramento, CA 95825; telephone 916–978–5593;
- Natural Resources Library, U.S. Department of the Interior, 1849 C Street, NW., Main Interior Building, Washington, DC 20240–0001;
- Alameda County Public Library, 2450 Stevenson Boulevard, Fremont, CA 94538; telephone 510–745–1400;
- Contra Costa County Library, 1750 Oak Park Boulevard, Pleasant Hill, CA 94523; telephone 925–646–6434;
- Fresno County Public Library, 2420 Mariposa Street, Fresno, CA 93721; telephone 559–488–3195;
- Kern County Public Library, 701 Truxton Avenue, Bakersfield, CA 93301; telephone 661–868–0701;
- Kings County Public Library, 401 North Douty Street, Hanford, CA 93230; telephone 559–582–0261;
- Merced County Public Library, 1312 South 7th Street, Los Banos, CA 95334; telephone 209–826–5254;
- San Joaquin County Public Library, 605 North El Dorado Street, Stockton, CA 95334; telephone 209–937–8221;
- San Luis Obispo County Public Library Bookmobile, PO Box 8107, San Luis Obispo, CA 93403; telephone for Bookmobile schedule/location 805–788–2145;
- Stanislaus County Public Library, 1500 I Street, Modesto, CA 95354; telephone 209–558–7800;
- UC Berkeley Water Resources Center Archives, 410 O'Brien Hall, Berkeley, CA 94720; telephone 510–642–2666.

Additional Information

Additional information is available online at *http://www.usbr.gov/mp/sccao/sld/index.html*. A Notice of Availability of the Draft EIS was published in the **Federal Register** on June 2, 2005 (70 FR 32370). The Final EIS contains responses to all comments received and reflects comments and any additional information received during the review period.

Reclamation's practice is to make any communication related to proposed projects, including names and home addresses, available for public review. Individual respondents may request that we withhold their home address from public disclosure, which will be honored to the extent allowable by law. There may be circumstances in which a respondent's identity may also be withheld from public disclosure, as allowable by law. If you wish to have your name and/or address withheld, you must state this prominently at the beginning of your communication. All submissions from organizations or businesses, and from individuals identifying themselves as representatives or officials of organizations or businesses, will be made available for public disclosure in their entirety.

Susan L. Ramos,

Assistant Regional Director, Mid-Pacific Region.

[FR Doc. E6–9184 Filed 6–12–06; 8:45 am]

BILLING CODE 4310–MN–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on November 18, 2005, Cambrex Charles City, Inc., 1205 11th Street, Charles City, Iowa 50616, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in Schedule II:

Drug	Schedule
Amphetamine (1100)	II
Methylphenidate (1724)	II
Dextropropoxyphene, bulk (non-dosage form) (9273).	II
Phenylacetone (8501)	II
Fentanyl (9801)	II

The company plans to manufacture the listed controlled substances in bulk for sales to its customers.

Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections being sent via regular mail may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative, Liaison and Policy Section (ODL); or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than August 14, 2006.

Dated: June 7, 2006.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E6–9177 Filed 6–12–06; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances; Notice of Application

Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in Schedule I or II and prior to issuing a regulation under 21 U.S.C. 952(a)(2)(B) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with 21 CFR 1301.34(a), this is notice that on January 26, 2006, Roche Diagnostics Operations, Inc., Attn: Regulatory Compliance, 9115 Hague Road, Indianapolis 46250, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed in Schedule I & II:

Drug	Schedule
Lysergic acid diethylamide (7315)	I
Tetrahydrocannabinols (7370)	I
Cocaine (9041)	II
Ecgonine (9180)	II
Methadone (9250)	II
Morphine (9300)	II
Alphamethadol (9605)	II

The company plans to import the listed controlled substances for the manufacture of diagnostic products for distribution to its customers.